Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
They should not be used in patients with: Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Pancreatitis: Inflammation of the pancreas (0.1-0.5% of patients) Symptoms: Severe abdominal pain that doesnt go away, with or without vomiting Action: Stop medication immediately and contact your healthcare provider Gallbladder Problems: Including gallstones (1-2% requiring surgery) Symptoms: Upper abdominal pain, fever, yellowing of skin or eyes Action: Seek immediate medical attention Kidney Problems: Particularly with severe dehydration from vomiting or diarrhea Prevention: Maintain adequate hydration throughout treatment Hypoglycemia: Low blood sugar, particularly in patients taking other diabetes medications Monitoring: Regular blood sugar checks if you have diabetes Safety Profile Comparison: SURMOUNT-5 Results In the head-to-head SURMOUNT-5 trial: Overall safety profiles were similar between Zepbound and Wegovy Most adverse events were gastrointestinal and mild to moderate Serious adverse events: 4.8% with Zepbound vs
Organic anion transporting polypeptides: pharmacology, toxicology, structure, and transport mechanisms
Still, the approval marks a meaningful expansion in access
Realmente ayuda a perder grasa
